Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20762257 | 0.88 | CTSA (0.39) | CTSASOS1PTGFR | |
| SCHEMBL20743906 | 0.88 | SOS1 (0.44) | GRIN1GRIN2BCTSASOS1PTGFR | |
| SCHEMBL19283711 | 0.87 | MAOB (0.43) | GRIN1GRIN2BHPGDCTSASOS1 | |
| SCHEMBL21821309 | 0.86 | MET (0.41) | GRIN1GRIN2BHPGDCTSASOS1 | |
| SCHEMBL20743169 | 0.85 | CTSA (0.39) | CTSASOS1PTGFR | |
| SCHEMBL30645020 | 0.85 | CTSA (0.39) | CTSASOS1PTGFR | |
| SCHEMBL19283561 | 0.84 | ITGA5 (0.45) | GRIN1GRIN2BHPGDRXFP1 | |
| SCHEMBL19283680 | 0.79 | CNR2 (0.37) | GRIN1GRIN2BCTSASOS1TACR1 | |
| SCHEMBL19301304 | 0.78 | ITGA5 (0.44) | CTSA | |
| SCHEMBL20762429 | 0.78 | CCNT1 (0.35) | CTSASOS1CDK9PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274092-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2022-03-15 | — | — | US | claimed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | claimed |
| EP-3419973-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-04-08 | — | — | EP | claimed |
| EP-3419973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2019-01-02 | — | — | EP | claimed |
| WO-2017144183-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2017-08-31 | — | — | WO | claimed |
| US-11274092-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2022-03-15 | — | — | US | disclosed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | disclosed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | disclosed |
| CN-109153667-B | Novel potassium channel inhibitors | 阿塞西翁制药公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3419973-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-04-08 | — | — | EP | disclosed |
| EP-3419973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017144183-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNN2, KCNN1 | GRIN1 264/4885GRIN2B 476/4885HPGD 2251/4885 |
| US-11274092-B2 | Potassium channel inhibitors | KCNJ2, KCNJ11, KCNJ1 | GRIN1 322/4885GRIN2B 514/4885HPGD 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.